Advertisement · 728 × 90
#
Hashtag
#PTC_Therapeutics
Advertisement · 728 × 90
Preview
PTC Therapeutics Welcomes Jessica Chutter to Board of Directors, a Move for Future Growth Jessica Chutter joins the Board of Directors at PTC Therapeutics, bringing her extensive experience in biotechnology investment banking.

PTC Therapeutics Welcomes Jessica Chutter to Board of Directors, a Move for Future Growth #United_States #PTC_Therapeutics #biotechnology #Warren,_New_Jersey #Jessica_Chutter

0 0 0 0
Preview
PTC Therapeutics Offers Competitive Stock Options to New Employees In a strategic move, PTC Therapeutics has approved stock options and RSUs for new hires under the Nasdaq inducement rule, enhancing employee compensation.

PTC Therapeutics Offers Competitive Stock Options to New Employees #USA #PTC_Therapeutics #stock_options #RSUs #Warren,_New_Jersey

0 0 0 0
Preview
PTC Therapeutics Announces Participation in Notable Investor Conferences This March PTC Therapeutics, Inc. will feature key executives at major healthcare conferences in March 2026, highlighting their advancements in rare disorders.

PTC Therapeutics Announces Participation in Notable Investor Conferences This March #USA #biopharmaceuticals #PTC_Therapeutics #Warren #Health_Conference

0 0 0 0
Preview
PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 PTC Therapeutics reported significant financial results for 2025, featuring product revenues of $831 million, boosted by Sephience's successful launch and promising growth.

PTC Therapeutics Announces Impressive Financial Performance and Key Updates for 2025 #USA #PTC_Therapeutics #Warren #Sephience #Evrysdi

0 0 0 0
Preview
PTC Therapeutics Takes Step Back on Translarna™ Regulatory Submission Following FDA Feedback PTC Therapeutics Inc. announces the withdrawal of the NDA for Translarna, aimed at treating Duchenne muscular dystrophy, following negative FDA feedback.

PTC Therapeutics Takes Step Back on Translarna™ Regulatory Submission Following FDA Feedback #USA #PTC_Therapeutics #Warren #Duchenne_Muscular_Dystrophy #Translarna

0 0 0 0
Preview
PTC Therapeutics Unveils Inducement Grants for New Employee Under Nasdaq Rule On January 2, 2026, PTC Therapeutics announced the granting of 300 restricted stock units under Nasdaq's inducement rules to a new employee.

PTC Therapeutics Unveils Inducement Grants for New Employee Under Nasdaq Rule #United_States #NASDAQ #PTC_Therapeutics #RSUs #Warren,_New_Jersey

0 0 0 0
Preview
PTC Therapeutics Secures Approval for Sephience in Japan to Treat PKU PTC Therapeutics has announced the approval of Sephience™ for treating phenylketonuria (PKU) in Japan, marking a significant milestone for patients and the company.

PTC Therapeutics Secures Approval for Sephience in Japan to Treat PKU #Japan #Tokyo #PTC_Therapeutics #Sephience #Phenylketonuria

0 0 0 0
Preview
PTC Therapeutics Announces New Inducement Grants Under Nasdaq Rule to Enhance Employee Compensation PTC Therapeutics has recently issued inducement grants to five new employees, combining stock options and restricted stock units, enhancing their compensation.

PTC Therapeutics Announces New Inducement Grants Under Nasdaq Rule to Enhance Employee Compensation #United_States #biopharmaceuticals #PTC_Therapeutics #Warren #NASDAQ_PTCT

0 0 0 0
Preview
PTC Therapeutics to Share Innovations at 44th J.P. Morgan Healthcare Conference Join PTC Therapeutics as CEO Matthew B. Klein presents groundbreaking updates at the 44th J.P. Morgan Healthcare Conference on Jan. 12, 2026.

PTC Therapeutics to Share Innovations at 44th J.P. Morgan Healthcare Conference #United_States #PTC_Therapeutics #Warren #Matthew_Klein #NASDAQ_PTCT

0 0 0 0
Preview
PTC Therapeutics Announces Stock Option Grants for New Employees Under Nasdaq Rules PTC Therapeutics reports the approval of stock options and restricted stock units for new hires as part of employment compensation, adhering to Nasdaq rules.

PTC Therapeutics Announces Stock Option Grants for New Employees Under Nasdaq Rules #United_States #PTC_Therapeutics #stock_options #RSUs #Warren,_N.J.

0 0 0 0
Preview
PTC Therapeutics Announces Upcoming R&D Day for Pipeline Insights PTC Therapeutics is set to host an R&D Day on Dec. 2, 2025, showcasing its innovative pipeline with key updates from leadership.

PTC Therapeutics Announces Upcoming R&D Day for Pipeline Insights #United_States #New_York #PTC_Therapeutics #R&D_Day #pipeline_updates

0 0 0 0
Preview
PTC Therapeutics Reports Strong Third Quarter 2025 Financial Performance and Sephience Launch PTC Therapeutics announces impressive Q3 2025 results, including robust revenue growth and the successful launch of Sephience, a promising treatment for PKU.

PTC Therapeutics Reports Strong Third Quarter 2025 Financial Performance and Sephience Launch #United_States #revenue_growth #PTC_Therapeutics #Warren,_New_Jersey #Sephience

0 0 0 0
Preview
PTC Therapeutics' Executives to Showcase Innovations at Significant Investor Conferences PTC Therapeutics, Inc. will present insights at key healthcare conferences in November and December, focusing on rare disorders.

PTC Therapeutics' Executives to Showcase Innovations at Significant Investor Conferences #USA #PTC_Therapeutics #Investor_Relations #Healthcare_Conferences #Warren,_New_Jersey

0 0 0 0
Preview
PTC Therapeutics Issues Inducement Stock Options for New Employees PTC Therapeutics, Inc. announces inducement grants, including stock options and restricted stock units, to two recent hires as part of their compensation package.

PTC Therapeutics Issues Inducement Stock Options for New Employees #USA #NASDAQ #PTC_Therapeutics #stock_options #Warren

0 0 0 0
Preview
PTC Therapeutics Announces Stock Option Grants for New Employees Under Nasdaq Rules PTC Therapeutics, Inc. has announced the approval of stock options and RSUs for 48 new hires as part of their employment compensation, following Nasdaq regulations.

PTC Therapeutics Announces Stock Option Grants for New Employees Under Nasdaq Rules #USA #NASDAQ #PTC_Therapeutics #stock_options #Warren

0 0 0 0
Preview
RareMed Solutions Partners with PTC Therapeutics to Enhance PKU Care with New Services RareMed Solutions is enhancing its relationship with PTC Therapeutics by expanding support services for the newly FDA-approved therapy for PKU, Sephience.

RareMed Solutions Partners with PTC Therapeutics to Enhance PKU Care with New Services #United_States #Pittsburgh #PTC_Therapeutics #Sephience #RareMed_Solutions

0 0 0 0
Preview
PTC Therapeutics Execs to Showcase Innovations at Major Investor Conferences PTC Therapeutics will present at notable investor conferences this September, highlighting advancements in biopharmaceuticals for rare disorders and their mission to transform medical care.

PTC Therapeutics Execs to Showcase Innovations at Major Investor Conferences #United_States #Healthcare_Conference #PTC_Therapeutics #Warren,_N.J. #NASDAQ:PTCT

0 0 0 0
Preview
PTC Therapeutics Faces Setback with FDA Complete Response on Vatiquinone PTC Therapeutics has encountered a challenge as the FDA issued a Complete Response Letter concerning their Vatiquinone NDA aimed at Friedreich's ataxia treatment.

PTC Therapeutics Faces Setback with FDA Complete Response on Vatiquinone #United_States #PTC_Therapeutics #Warren #Vatiquinone #Friedreich's_Ataxia

0 0 0 0
Preview
PTC Therapeutics Sets the Stage for Growth with Q2 2025 Corporate Update and Financial Performance In their latest corporate update, PTC Therapeutics reveals significant progress with Sephience's launch and robust financial results, marking another promising quarter.

PTC Therapeutics Sets the Stage for Growth with Q2 2025 Corporate Update and Financial Performance #USA #financial_results #PTC_Therapeutics #Warren,_NJ #Sephience

0 0 0 0
Preview
Orsini Partners with PTC Therapeutics to Enhance Care for PKU Patients with SEPHIENCE Orsini, recognized for its dedication to rare disease management, teams up with PTC Therapeutics to support the distribution of SEPHIENCE, a crucial PKU therapy.

Orsini Partners with PTC Therapeutics to Enhance Care for PKU Patients with SEPHIENCE #United_States #Elk_Grove_Village #PTC_Therapeutics #Sephience #Orsini_Pharmacy

0 0 0 0
Preview
Sephience™ Receives EU Approval for Treating PKU in All Ages PTC Therapeutics announces the European Commission's approval of Sephience™ to treat PKU in all age groups, marking a significant advance in metabolic disorder treatments.

Sephience™ Receives EU Approval for Treating PKU in All Ages #None #PTC_Therapeutics #Sephience #Phenylketonuria

0 0 0 0
Preview
PTC Therapeutics Faces Securities Fraud Investigation - Shareholders Can Join The Schall Law Firm is investigating potential securities law violations by PTC Therapeutics, inviting affected investors to participate in the inquiry.

PTC Therapeutics Faces Securities Fraud Investigation - Shareholders Can Join #USA #Los_Angeles #Schall_Law_Firm #Securities_Fraud #PTC_Therapeutics

0 0 0 0
Preview
Sephience™ Receives EU Marketing Authorization for PKU Treatment: A Major Leap Forward PTC Therapeutics announces Sephience™ has gained marketing approval from the European Commission to treat phenylketonuria for all ages and severities.

Sephience™ Receives EU Marketing Authorization for PKU Treatment: A Major Leap Forward #None #PTC_Therapeutics #PKU #Sephience

0 0 0 0
Preview
Pomerantz Law Firm Launches Investigation into PTC Therapeutics for Investor Claims The Pomerantz Law Firm investigates claims for investors of PTC Therapeutics, Inc. concerning potential securities fraud linked to recent study results.

Pomerantz Law Firm Launches Investigation into PTC Therapeutics for Investor Claims #United_States #New_York #PTC_Therapeutics #Pomerantz_Law_Firm #PTCT

0 0 0 0
Preview
PTC Therapeutics Expands Team with New Stock Option Grants for 34 Employees On June 16, 2025, PTC Therapeutics granted stock options and RSUs to 34 new employees, aiming to enhance its workforce as part of its growth strategy.

PTC Therapeutics Expands Team with New Stock Option Grants for 34 Employees #United_States #biopharmaceuticals #PTC_Therapeutics #stock_options #Warren

0 0 0 0
Preview
PTC Therapeutics Investors Alert: Scrutiny of Securities Practices Unfolds The Pomerantz Law Firm is conducting an investigation into PTC Therapeutics, Inc. over potential securities fraud claims affecting investors.

PTC Therapeutics Investors Alert: Scrutiny of Securities Practices Unfolds #United_States #New_York #Securities_Fraud #PTC_Therapeutics #Pomerantz_LLP

0 0 0 0
Preview
Pomerantz Law Firm Launches Investigation into PTC Therapeutics Following Significant Stock Plunge Investors of PTC Therapeutics are under scrutiny as Pomerantz Law Firm investigates potential securities fraud related to recent stock declines.

Pomerantz Law Firm Launches Investigation into PTC Therapeutics Following Significant Stock Plunge #USA #New_York #Securities_Fraud #PTC_Therapeutics #Pomerantz_Law_Firm

0 0 0 0
Preview
Pomerantz Law Firm Launches Investigation for PTC Therapeutics Investors Pomerantz Law Firm is currently probing claims against PTC Therapeutics, Inc. regarding potential securities fraud and business malpractice.

Pomerantz Law Firm Launches Investigation for PTC Therapeutics Investors #United_States #New_York #Securities_Fraud #PTC_Therapeutics #Pomerantz_Law_Firm

0 0 0 0
Preview
Pomerantz Law Firm Investigates Potential Securities Fraud at PTC Therapeutics, Inc. Pomerantz LLP is actively looking into potential securities fraud involving PTC Therapeutics, Inc. Here's what investors need to know.

Pomerantz Law Firm Investigates Potential Securities Fraud at PTC Therapeutics, Inc. #United_States #New_York #Securities_Fraud #PTC_Therapeutics #Pomerantz_LLP

0 0 0 0
Preview
Pomerantz Law Firm Investigates PTC Therapeutics Stock Fraud Allegations for Investors Pomerantz LLP is probing possible securities fraud claims for investors of PTC Therapeutics, Inc. following significant stock price drop.

Pomerantz Law Firm Investigates PTC Therapeutics Stock Fraud Allegations for Investors #USA #New_York #PTC_Therapeutics #Pomerantz_LLP #stock_fraud

0 0 0 0